The Atherogenic Index of Plasma（AIP） in Patients With Atrial Fibrillation

Launched by SUN YAT-SEN MEMORIAL HOSPITAL OF SUN YAT-SEN UNIVERSITY · Jul 25, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "The Atherogenic Index of Plasma (AIP) in Patients With Atrial Fibrillation," aims to learn more about how a specific measurement called the Atherogenic Index of Plasma (AIP) relates to patients who have atrial fibrillation (AF). Atrial fibrillation is a condition where the heart beats irregularly, which can lead to serious complications. The study will look at whether higher or lower AIP levels are connected to the occurrence of AF and other heart-related events, such as heart failure or blood clots. Researchers will collect information from participants, including their medical history and test results, to better understand these relationships.

To participate in this study, individuals need to be at least 18 years old and have been diagnosed with atrial fibrillation through specific heart monitoring tests. They should also fall into a "low-intermediate" risk category for stroke based on a scoring system. However, certain patients, such as those with specific heart diseases or serious health conditions, will not be eligible to join. Since the study is not yet recruiting, there will be no immediate participation, but it represents an important step in understanding the connections between AIP and heart health in AF patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Atrial fibrillation was detected by electrocardiogram or 24-hour holter or portable electrocardiogram monitor;
• • 2. age ≥18 years old;
• • 3. "low-intermediate" risk group of AF cardioembolic stroke: male patients with CHA2DS2-VASc score 0-1 or female patients with CHA2DS2-VASc score 1-2
• Exclusion Criteria:
• • 1. patients with rheumatic heart disease, congenital heart disease, cardiomyopathy, hematological diseases, severe hepatic and renal insufficiency and connective tissue diseases;
• • 2. Echocardiography showed valvular heart disease;
• • 3. patients with transient atrial fibrillation secondary to reversible causes: hyperthyroidism, acute pulmonary embolism, recent surgery, acute myocardial infarction, etc.
• • 4. severe carotid artery stenosis and intracranial artery stenosis;
• • 5. AF patients with recent major surgery.
• • 6. patients with serious lack of clinical data.